Orphan Drugs Market 2027 By Active Ingredients, Disease and End User | The Insight Partners

Orphan Drugs Market to 2027 - Global Analysis and Forecasts by Active ingredients (Obinutuzumab, Lenalidomide, Brentuximab, Vedotin, Riociguat, Ofatumumab, Nelarabine, Bosutinib, Mannitol, Carglumic acid, Aztreonam, Histamine hydrochloride, Eliglustat, Cabozantinib, Ramucirumab, Decitabine, Defibrotide) ; Disease (Hodgkin lymphoma, Paroxysmal nocturnal hemoglobinuria, Chronic thromboembolic pulmonary hypertension (CTEPH) , Chronic lymphocytic leukemia, Chronic Myeloid Leukaemia, T-cell acute lymphoblastic leukemia (T-ALL) , Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) , Cystic fibrosis (CF) , acute myeloid leukaemia, Multiple Myeloma, Isovaleric acidaemia, Gaucher disease type 1 (GD1) , Metastatic medullary thyroid carcinoma, Advanced gastric cancer or gastro-esophageal junction adenocarcinoma, Secondary Acute myeloid leukemia (AML) , Severe hepatic venoocclusive disease (VOD) / sinusoidal obstructive syndrome (SOS) ) ; End User (Hospitals, Ambulatory Surgical Centers)

Report Code: TIPRE00005799 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION

Orphan Drugs are pharmaceutical drugs that remain commercially undeveloped. These are vaccines, medicine or in-vivo diagnostic agent, which are intended to treat, diagnose and prevent a rare disease.

MARKET DYNAMICS

The Orphan Drugs market is anticipated to grow in the forecast, owing to the factors such as prevalence of rare diseases, rising awareness among the people, increasing r&d investments, development of drugs, and advancements and innovations.

MARKET SCOPE

The "Global Orphan Drugs Market Analysis to 2027" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of Orphan Drugs market with detailed market segmentation by active ingredients, disease, end user and geography. The global Orphan Drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Orphan Drugs market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global Orphan Drugs market is segmented on the basis of active ingredients, disease and end user. Based on active ingredients the market is segmented into Obinutuzumab, Lenalidomide, Brentuximab, Vedotin, Riociguat, Ofatumumab, Nelarabine, Bosutinib, Mannitol, Carglumic acid, Aztreonam, Histamine hydrochloride, Eliglustat, Cabozantinib, Ramucirumab, Decitabine, Defibrotide. Based on disease the market is segmented into Hodgkin lymphoma, Paroxysmal nocturnal hemoglobinuria, Chronic thromboembolic pulmonary hypertension (CTEPH), Chronic lymphocytic leukemia, Chronic Myeloid Leukaemia, T-cell acute lymphoblastic leukemia (T-ALL), Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML), Cystic fibrosis (CF), acute myeloid leukaemia, Multiple Myeloma, Isovaleric acidaemia, Gaucher disease type 1 (GD1), Metastatic medullary thyroid carcinoma, Advanced gastric cancer or gastro-esophageal junction adenocarcinoma, Secondary Acute myeloid leukemia (AML), Severe hepatic venoocclusive disease (VOD)/ sinusoidal obstructive syndrome (SOS). Based on end user the market is segmented into Hospitals, Ambulatory Surgical Centers.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Orphan Drugs market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Orphan Drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Orphan Drugs market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Orphan Drugs market in these regions.

MARKET PLAYERS
The reports cover key developments in the Orphan Drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from Orphan Drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for Orphan Drugs market in the global market. Below mentioned is the list of few companies engaged in the Orphan Drugs market.

The report also includes the profiles of Orphan Drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Company
  • Alexion
  • CELGENE CORPORATION
  • Novartis AG
  • Takeda Pharmaceuticals Company Limited
  • Biogen
  • Bristol-Myers Squibb Company
  • Bayer AG
  • Sanofi
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Orphan Drugs Market - By Active ingredients
1.3.2 Orphan Drugs Market - By Disease
1.3.3 Orphan Drugs Market - By End User
1.3.4 Orphan Drugs Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ORPHAN DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ORPHAN DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ORPHAN DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. ORPHAN DRUGS - GLOBAL MARKET OVERVIEW
6.2. ORPHAN DRUGS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. ORPHAN DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - ACTIVE INGREDIENTS
7.1. OVERVIEW
7.2. ACTIVE INGREDIENTS MARKET FORECASTS AND ANALYSIS
7.3. OBINUTUZUMAB
7.3.1. Overview
7.3.2. Obinutuzumab Market Forecast and Analysis
7.4. LENALIDOMIDE
7.4.1. Overview
7.4.2. Lenalidomide Market Forecast and Analysis
7.5. BRENTUXIMAB
7.5.1. Overview
7.5.2. Brentuximab Market Forecast and Analysis
7.6. VEDOTIN
7.6.1. Overview
7.6.2. Vedotin Market Forecast and Analysis
7.7. RIOCIGUAT
7.7.1. Overview
7.7.2. Riociguat Market Forecast and Analysis
7.8. OFATUMUMAB
7.8.1. Overview
7.8.2. Ofatumumab Market Forecast and Analysis
7.9. NELARABINE
7.9.1. Overview
7.9.2. Nelarabine Market Forecast and Analysis
7.10. BOSUTINIB
7.10.1. Overview
7.10.2. Bosutinib Market Forecast and Analysis
7.11. MANNITOL
7.11.1. Overview
7.11.2. Mannitol Market Forecast and Analysis
7.12. CARGLUMIC ACID
7.12.1. Overview
7.12.2. Carglumic acid Market Forecast and Analysis
7.13. AZTREONAM
7.13.1. Overview
7.13.2. Aztreonam Market Forecast and Analysis
7.14. HISTAMINE HYDROCHLORIDE
7.14.1. Overview
7.14.2. Histamine hydrochloride Market Forecast and Analysis
7.15. ELIGLUSTAT
7.15.1. Overview
7.15.2. Eliglustat Market Forecast and Analysis
7.16. CABOZANTINIB
7.16.1. Overview
7.16.2. Cabozantinib Market Forecast and Analysis
7.17. RAMUCIRUMAB
7.17.1. Overview
7.17.2. Ramucirumab Market Forecast and Analysis
7.18. DECITABINE
7.18.1. Overview
7.18.2. Decitabine Market Forecast and Analysis
7.19. DEFIBROTIDE
7.19.1. Overview
7.19.2. Defibrotide Market Forecast and Analysis
8. ORPHAN DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - DISEASE
8.1. OVERVIEW
8.2. DISEASE MARKET FORECASTS AND ANALYSIS
8.3. HODGKIN LYMPHOMA
8.3.1. Overview
8.3.2. Hodgkin lymphoma Market Forecast and Analysis
8.4. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
8.4.1. Overview
8.4.2. Paroxysmal nocturnal hemoglobinuria Market Forecast and Analysis
8.5. CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH)
8.5.1. Overview
8.5.2. Chronic thromboembolic pulmonary hypertension (CTEPH) Market Forecast and Analysis
8.6. CHRONIC LYMPHOCYTIC LEUKEMIA
8.6.1. Overview
8.6.2. Chronic lymphocytic leukemia Market Forecast and Analysis
8.7. CHRONIC MYELOID LEUKAEMIA
8.7.1. Overview
8.7.2. Chronic Myeloid Leukaemia Market Forecast and Analysis
8.8. T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL)
8.8.1. Overview
8.8.2. T-cell acute lymphoblastic leukemia (T-ALL) Market Forecast and Analysis
8.9. PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOGENOUS LEUKAEMIA (PH+ CML)
8.9.1. Overview
8.9.2. Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) Market Forecast and Analysis
8.10. CYSTIC FIBROSIS (CF)
8.10.1. Overview
8.10.2. Cystic fibrosis (CF) Market Forecast and Analysis
8.11. ACUTE MYELOID LEUKAEMIA
8.11.1. Overview
8.11.2. acute myeloid leukaemia Market Forecast and Analysis
8.12. MULTIPLE MYELOMA
8.12.1. Overview
8.12.2. Multiple Myeloma Market Forecast and Analysis
8.13. ISOVALERIC ACIDAEMIA
8.13.1. Overview
8.13.2. Isovaleric acidaemia Market Forecast and Analysis
8.14. GAUCHER DISEASE TYPE 1 (GD1)
8.14.1. Overview
8.14.2. Gaucher disease type 1 (GD1) Market Forecast and Analysis
8.15. METASTATIC MEDULLARY THYROID CARCINOMA
8.15.1. Overview
8.15.2. Metastatic medullary thyroid carcinoma Market Forecast and Analysis
8.16. ADVANCED GASTRIC CANCER OR GASTRO-ESOPHAGEAL JUNCTION ADENOCARCINOMA
8.16.1. Overview
8.16.2. Advanced gastric cancer or gastro-esophageal junction adenocarcinoma Market Forecast and Analysis
8.17. SECONDARY ACUTE MYELOID LEUKEMIA (AML)
8.17.1. Overview
8.17.2. Secondary Acute myeloid leukemia (AML) Market Forecast and Analysis
8.18. SEVERE HEPATIC VENOOCCLUSIVE DISEASE (VOD)/ SINUSOIDAL OBSTRUCTIVE SYNDROME (SOS)
8.18.1. Overview
8.18.2. Severe hepatic venoocclusive disease (VOD)/ sinusoidal obstructive syndrome (SOS) Market Forecast and Analysis
9. ORPHAN DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. AMBULATORY SURGICAL CENTERS.
9.4.1. Overview
9.4.2. Ambulatory Surgical Centers. Market Forecast and Analysis
10. ORPHAN DRUGS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Orphan Drugs Market Overview
10.1.2 North America Orphan Drugs Market Forecasts and Analysis
10.1.3 North America Orphan Drugs Market Forecasts and Analysis - By Active ingredients
10.1.4 North America Orphan Drugs Market Forecasts and Analysis - By Disease
10.1.5 North America Orphan Drugs Market Forecasts and Analysis - By End User
10.1.6 North America Orphan Drugs Market Forecasts and Analysis - By Countries
10.1.6.1 United States Orphan Drugs Market
10.1.6.1.1 United States Orphan Drugs Market by Active ingredients
10.1.6.1.2 United States Orphan Drugs Market by Disease
10.1.6.1.3 United States Orphan Drugs Market by End User
10.1.6.2 Canada Orphan Drugs Market
10.1.6.2.1 Canada Orphan Drugs Market by Active ingredients
10.1.6.2.2 Canada Orphan Drugs Market by Disease
10.1.6.2.3 Canada Orphan Drugs Market by End User
10.1.6.3 Mexico Orphan Drugs Market
10.1.6.3.1 Mexico Orphan Drugs Market by Active ingredients
10.1.6.3.2 Mexico Orphan Drugs Market by Disease
10.1.6.3.3 Mexico Orphan Drugs Market by End User
10.2. EUROPE
10.2.1 Europe Orphan Drugs Market Overview
10.2.2 Europe Orphan Drugs Market Forecasts and Analysis
10.2.3 Europe Orphan Drugs Market Forecasts and Analysis - By Active ingredients
10.2.4 Europe Orphan Drugs Market Forecasts and Analysis - By Disease
10.2.5 Europe Orphan Drugs Market Forecasts and Analysis - By End User
10.2.6 Europe Orphan Drugs Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Orphan Drugs Market
10.2.6.1.1 Germany Orphan Drugs Market by Active ingredients
10.2.6.1.2 Germany Orphan Drugs Market by Disease
10.2.6.1.3 Germany Orphan Drugs Market by End User
10.2.6.2 France Orphan Drugs Market
10.2.6.2.1 France Orphan Drugs Market by Active ingredients
10.2.6.2.2 France Orphan Drugs Market by Disease
10.2.6.2.3 France Orphan Drugs Market by End User
10.2.6.3 Italy Orphan Drugs Market
10.2.6.3.1 Italy Orphan Drugs Market by Active ingredients
10.2.6.3.2 Italy Orphan Drugs Market by Disease
10.2.6.3.3 Italy Orphan Drugs Market by End User
10.2.6.4 Spain Orphan Drugs Market
10.2.6.4.1 Spain Orphan Drugs Market by Active ingredients
10.2.6.4.2 Spain Orphan Drugs Market by Disease
10.2.6.4.3 Spain Orphan Drugs Market by End User
10.2.6.5 United Kingdom Orphan Drugs Market
10.2.6.5.1 United Kingdom Orphan Drugs Market by Active ingredients
10.2.6.5.2 United Kingdom Orphan Drugs Market by Disease
10.2.6.5.3 United Kingdom Orphan Drugs Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Orphan Drugs Market Overview
10.3.2 Asia-Pacific Orphan Drugs Market Forecasts and Analysis
10.3.3 Asia-Pacific Orphan Drugs Market Forecasts and Analysis - By Active ingredients
10.3.4 Asia-Pacific Orphan Drugs Market Forecasts and Analysis - By Disease
10.3.5 Asia-Pacific Orphan Drugs Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Orphan Drugs Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Orphan Drugs Market
10.3.6.1.1 Australia Orphan Drugs Market by Active ingredients
10.3.6.1.2 Australia Orphan Drugs Market by Disease
10.3.6.1.3 Australia Orphan Drugs Market by End User
10.3.6.2 China Orphan Drugs Market
10.3.6.2.1 China Orphan Drugs Market by Active ingredients
10.3.6.2.2 China Orphan Drugs Market by Disease
10.3.6.2.3 China Orphan Drugs Market by End User
10.3.6.3 India Orphan Drugs Market
10.3.6.3.1 India Orphan Drugs Market by Active ingredients
10.3.6.3.2 India Orphan Drugs Market by Disease
10.3.6.3.3 India Orphan Drugs Market by End User
10.3.6.4 Japan Orphan Drugs Market
10.3.6.4.1 Japan Orphan Drugs Market by Active ingredients
10.3.6.4.2 Japan Orphan Drugs Market by Disease
10.3.6.4.3 Japan Orphan Drugs Market by End User
10.3.6.5 South Korea Orphan Drugs Market
10.3.6.5.1 South Korea Orphan Drugs Market by Active ingredients
10.3.6.5.2 South Korea Orphan Drugs Market by Disease
10.3.6.5.3 South Korea Orphan Drugs Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Orphan Drugs Market Overview
10.4.2 Middle East and Africa Orphan Drugs Market Forecasts and Analysis
10.4.3 Middle East and Africa Orphan Drugs Market Forecasts and Analysis - By Active ingredients
10.4.4 Middle East and Africa Orphan Drugs Market Forecasts and Analysis - By Disease
10.4.5 Middle East and Africa Orphan Drugs Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Orphan Drugs Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Orphan Drugs Market
10.4.6.1.1 South Africa Orphan Drugs Market by Active ingredients
10.4.6.1.2 South Africa Orphan Drugs Market by Disease
10.4.6.1.3 South Africa Orphan Drugs Market by End User
10.4.6.2 Saudi Arabia Orphan Drugs Market
10.4.6.2.1 Saudi Arabia Orphan Drugs Market by Active ingredients
10.4.6.2.2 Saudi Arabia Orphan Drugs Market by Disease
10.4.6.2.3 Saudi Arabia Orphan Drugs Market by End User
10.4.6.3 U.A.E Orphan Drugs Market
10.4.6.3.1 U.A.E Orphan Drugs Market by Active ingredients
10.4.6.3.2 U.A.E Orphan Drugs Market by Disease
10.4.6.3.3 U.A.E Orphan Drugs Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Orphan Drugs Market Overview
10.5.2 South and Central America Orphan Drugs Market Forecasts and Analysis
10.5.3 South and Central America Orphan Drugs Market Forecasts and Analysis - By Active ingredients
10.5.4 South and Central America Orphan Drugs Market Forecasts and Analysis - By Disease
10.5.5 South and Central America Orphan Drugs Market Forecasts and Analysis - By End User
10.5.6 South and Central America Orphan Drugs Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Orphan Drugs Market
10.5.6.1.1 Brazil Orphan Drugs Market by Active ingredients
10.5.6.1.2 Brazil Orphan Drugs Market by Disease
10.5.6.1.3 Brazil Orphan Drugs Market by End User
10.5.6.2 Argentina Orphan Drugs Market
10.5.6.2.1 Argentina Orphan Drugs Market by Active ingredients
10.5.6.2.2 Argentina Orphan Drugs Market by Disease
10.5.6.2.3 Argentina Orphan Drugs Market by End User
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. ORPHAN DRUGS MARKET, KEY COMPANY PROFILES
12.1. F. HOFFMANN-LA ROCHE LTD
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. ELI LILLY AND COMPANY
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. ALEXION
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. CELGENE CORPORATION
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. NOVARTIS AG
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. TAKEDA PHARMACEUTICALS COMPANY LIMITEDBIOGEN
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. BRISTOL-MYERS SQUIBB COMPANY
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. BAYER AG
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. SANOFI
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

  1.  F. Hoffmann-La Roche Ltd
  2.  Eli Lilly and Company
  3.  Alexion
  4.  CELGENE CORPORATION
  5.  Novartis AG
  6.  Takeda Pharmaceuticals Company Limited
  7.  Biogen
  8.  Bristol-Myers Squibb Company
  9.  Bayer AG
  10.  Sanofi